Freeport-McMoRan Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Freeport-McMoRan Inc trades at $69.18 (market cap $96.42B), while State Street SPDR S&P Biotech ETF trades at $159.24. The key difference: Freeport-McMoRan Inc pays a 0.87% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| FCX | XBI | |
|---|---|---|
Market Cap | $96.42B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $71.73 | $164.28 |
52-Week Low | $35.34 | $86.92 |
Enterprise Value | $102.70B | — |
Dividend Yield | 0.87% | — |
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.23, down 1.84% on the day, with a bullish technical signal supported by moving averages and strong support at $68. The company reported Q2 2026 EPS of $0.68, beating estimates, and maintains robust cash flow from operations of $5.61 billion in 2025. Recent news highlights growth from Grasberg ramp-up and copper market tailwinds.
Outlook is positive with a consensus price target of $73.85, reflecting 6.7% upside, driven by earnings beats and expansion projects. Risks include commodity price volatility and execution challenges at new mines. Analyst sentiment is strongly bullish with 61% buy ratings, but overbought RSI levels suggest near-term caution.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Trailing returns across standard periods
Latest headlines on both assets
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →